Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00401687 · ClinicalTrials.gov registry record · Phase 4

DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function

A Phase 4 study of Ventricular Ejection Fraction, sponsored by Lantheus Medical Imaging.

Completed
Registry status
Phase 4
Development phase
131
Enrollment target
10
Study locations

NCT00401687 is a Phase 4 study of Ventricular Ejection Fraction that has completed, run by Lantheus Medical Imaging. The registered enrollment target is 131 participants. The trial reports 10 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00401687, a Phase 4 study of Ventricular Ejection Fraction, has completed, sponsored by Lantheus Medical Imaging.

COMPLETED
Registry status
Phase 4
Development phase
131 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this clinical research study is to demonstrate the ability of Definity® enhanced versus unenhanced cardiac ultrasound to improve the accuracy and reproducibility of left ventricular ejection fraction (EF) when compared to magnetic resonance imaging (MRI).

Interventions

  • DRUG Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension

Study Locations (10)

Arizona

  • University of Arizona - Tucson

Illinois

  • University of Chicago Medical Center - Chicago

Maryland

  • Washington Hospital Center - Washington DC

Missouri

  • Saint Lukes Mid America Heart Institute - Kansas City

Nebraska

  • University of Nebraska Medical Center - Omaha

North Carolina

  • Duke University Medical Center - Durham

Ohio

  • Cleveland Clinic Foundation - Cleveland

Oregon

  • Oregon Health & Science University - Portland

Trial Details

FieldValue
Enrollment Target 131 participants
Start Date 2006-07
Est. Completion 2008-04
Phase Phase 4

Sponsor

Lantheus Medical Imaging

22 total trials

What the Registry Record Tells You About NCT00401687

The ClinicalTrials.gov registry entry for NCT00401687 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lantheus Medical Imaging, which has 22 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ventricular Ejection Fraction appearing as the primary indexed condition, and to 1 intervention - of which Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension is the first listed.

NCT00401687 reports 10 study locations spanning 10 distinct geographic areas - top geographies include Arizona, Illinois, Maryland.

Frequently Asked Questions

What is clinical trial NCT00401687 about?

NCT00401687 is a clinical study titled "DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function". The purpose of this clinical research study is to demonstrate the ability of Definity® enhanced versus unenhanced cardiac ultrasound to improve the accuracy and reproducibility of left ventricular ejection fraction (EF) when compared to magnetic resonance imaging (MRI).

What is the current status of trial NCT00401687?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 131 participants. The study started on 2006-07. Estimated completion is 2008-04.

What conditions does trial NCT00401687 study?

This clinical trial studies the following conditions: Ventricular Ejection Fraction.

What interventions are being tested in trial NCT00401687?

The interventions under investigation include: Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension (DRUG).

Who is sponsoring clinical trial NCT00401687?

This trial is sponsored by Lantheus Medical Imaging, which has 22 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00401687 being conducted?

This trial has 10 study locations across Arizona, Illinois, Maryland, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ventricular Ejection Fraction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.